Full-Time

Patient Advocacy Lead

Neuroscience

Confirmed live in the last 24 hours

Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm focused on R&D

Compensation Overview

$169.4k - $266.2k/yr

+ Short-term Incentives + Long-term Incentives

Senior, Expert

Cambridge, MA, USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Bachelors degree, preferable in Health related field
  • 10+ years experience in Pharm/Biotech company
  • 5+ years experience in Policy/Advocacy related role
  • European, International or Global advocacy experience required
  • Country level advocacy work and experience is preferable
  • Proven track record of conducting Advocacy initiatives, programs or events
Responsibilities
  • This role will be a key Takeda lead representative with global reach for external stakeholders across our therapeutic areas in Neuroscience
  • Develop strategies to lead engagement with patient organizations aligned with Takeda’s therapeutic focus; identify, create, and sustain innovative/strategic partnerships to support therapeutic and brand goals
  • Evaluates, monitors, and analyzes policy environment at the global, regional and LOC (i.e. local) levels and identify trends, obstacles and opportunities for business and patients.
  • Ensures coordination of advocacy relations between regions and LOCs, preparing the global advocacy landscape, trends and patient group events, initiatives and activities relevant to the franchise and disease areas
  • Strong cross-functional interaction and communication required with the franchise leaders, Market Access franchise lead as well as regions and LOCs as needed to advise the policy/advocacy strategies and tactics that are reflective and validated to support the needs of patient communities
  • Oversee and manage all therapeutic area global patient interactions, meetings and initiatives and provide strategic counsel to function leaders, brand teams, market access function, medical and policy leads to inform and ensure effective alignment with franchise corporate policy positions.
  • Provide communications and regular updates to franchise on patient advocacy and engagement activities occurring both internally and externally
  • Facilitate and guide appropriate interactions between Takeda staff and relevant patient communities in all forms
  • Lead, advocate and intervene with compliance expertise in the field of industry and patient organization relations
  • Lead in insuring a smooth process in place for patient organization donations & sponsorships requests and approvals in cooperation with relevant internal stakeholders
Desired Qualifications
  • Country level advocacy work and experience is preferable

Takeda Pharmaceutical Company Limited is a global biopharmaceutical firm that focuses on developing and delivering treatments and vaccines. The company invests heavily in research and development to create new molecular entities (NMEs) and has a pipeline of 11 NMEs, aiming for up to 15 product launches by FY2024. Takeda's products are designed to meet the needs of healthcare providers, hospitals, and patients around the world. What sets Takeda apart from its competitors is its strong commitment to patient-centric values and environmental sustainability, recognizing the connection between human health and environmental health. The company's goal is to innovate and provide life-changing therapies while ensuring that patient needs are prioritized.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Simplify Jobs

Simplify's Take

What believers are saying

  • Takeda's focus on personalized medicine can increase treatment efficacy and patient satisfaction.
  • Expansion in Southeast Asia offers opportunities for increased market presence and revenue growth.
  • Collaborations with tech companies can accelerate R&D processes and reduce costs.

What critics are saying

  • Data breach could lead to financial and reputational damage for Takeda.
  • Antitrust litigation with Meijer may result in financial penalties or business practice changes.
  • High financial commitments in partnerships could strain resources if outcomes are not achieved.

What makes Takeda unique

  • Takeda has a 240-year history in the biopharmaceutical industry.
  • The company emphasizes patient-centric values in its operations and R&D efforts.
  • Takeda's robust pipeline includes 11 NMEs with plans for 15 product launches by FY2024.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Company News

CyberNews
Apr 15th, 2025
Hackers want $75,000 for data allegedly stolen from Takeda

A new account on an illicit forum bearing the moniker "beltway" claims that in April 2025, it exported around two million rows of user information from Takeda.com.

MLex
Mar 4th, 2025
Meijer seeks quick appeal in US antitrust case against Takeda

( March 4, 2025, 17:06 GMT | Official Statement) - MLex Summary: Meijer asked a US federal judge for leave to immediately appeal an order that sent its antitrust case against Takeda Pharmaceuticals over the drug Amitiza to arbitration.

BioSpace
Mar 3rd, 2025
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial

Protagonist, which will receive a $25 million milestone from Takeda thanks to the positive results, plans to submit the findings to regulators.

Access Health
Mar 3rd, 2025
Strengthening Access to Medicines in Southeast Asia: Highlights from Southeast Asia Access to Medicine (SEA AtM) Summit

ACCESS Health International, in collaboration with AVPN, SingHealth Duke-NUS Global Health Institute, and Takeda, successfully co-hosted the first Southeast Asia Access to Medicine (SEA AtM) Summit in Bangkok.

Pharmaceutical Technology
Feb 25th, 2025
Takeda broadens its deal with BridGene for up to $770m

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology.